Discussion
Latus Bio plans to submit an application with the U.S. Food and Drug Administration (FDA) to move LTS-201, a one-time gene therapy for Huntington’s disease, into clinical trials. The application, which the company expects to file in the current quarter, leverages promising results in Huntington’s animal models showing…